001     132628
005     20240229105023.0
024 7 _ |a 10.1016/j.mayocp.2017.10.023
|2 doi
024 7 _ |a pmid:29502561
|2 pmid
024 7 _ |a pmc:PMC5870793
|2 pmc
024 7 _ |a 0025-6196
|2 ISSN
024 7 _ |a 1942-5546
|2 ISSN
024 7 _ |a altmetric:33935684
|2 altmetric
037 _ _ |a DKFZ-2018-00288
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Block, Matthew S
|b 0
245 _ _ |a MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
260 _ _ |a Rochester, Minn.
|c 2018
|b Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1525329978_1538
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival.We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong).Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P<.001 for both). In HGSOC, strong MyD88 expression was modestly associated with shortened overall survival (hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P=.04) but was also associated with advanced stage (P<.001). The expression of TLR4 was not associated with survival. In low-grade serous ovarian cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable survival (HR [95% CI], 0.49 [0.29-0.84] and 0.44 [0.21-0.89], respectively; P=.009 and P=.02, respectively).Results are consistent with an association between strong MyD88 staining and advanced stage and poorer survival in HGSOC and demonstrate correlation between strong MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological differences between the 2 serous histotypes.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Vierkant, Robert A
|b 1
700 1 _ |a Rambau, Peter F
|b 2
700 1 _ |a Winham, Stacey J
|b 3
700 1 _ |a Wagner, Philipp
|b 4
700 1 _ |a Traficante, Nadia
|b 5
700 1 _ |a Tołoczko, Aleksandra
|b 6
700 1 _ |a Tiezzi, Daniel G
|b 7
700 1 _ |a Taran, Florin Andrei
|b 8
700 1 _ |a Sinn, Peter
|b 9
700 1 _ |a Sieh, Weiva
|b 10
700 1 _ |a Sharma, Raghwa
|b 11
700 1 _ |a Rothstein, Joseph H
|b 12
700 1 _ |a Ramón Y Cajal, Teresa
|b 13
700 1 _ |a Paz-Ares, Luis
|b 14
700 1 _ |a Oszurek, Oleg
|b 15
700 1 _ |a Orsulic, Sandra
|b 16
700 1 _ |a Ness, Roberta B
|b 17
700 1 _ |a Nelson, Gregg
|b 18
700 1 _ |a Modugno, Francesmary
|b 19
700 1 _ |a Menkiszak, Janusz
|b 20
700 1 _ |a McGuire, Valerie
|b 21
700 1 _ |a McCauley, Bryan M
|b 22
700 1 _ |a Mack, Marie
|b 23
700 1 _ |a Lubiński, Jan
|b 24
700 1 _ |a Longacre, Teri A
|b 25
700 1 _ |a Li, Zheng
|b 26
700 1 _ |a Lester, Jenny
|b 27
700 1 _ |a Kennedy, Catherine J
|b 28
700 1 _ |a Kalli, Kimberly R
|b 29
700 1 _ |a Jung, Audrey Ying-Chee
|0 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
|b 30
|u dkfz
700 1 _ |a Johnatty, Sharon E
|b 31
700 1 _ |a Jimenez-Linan, Mercedes
|b 32
700 1 _ |a Jensen, Allan
|b 33
700 1 _ |a Intermaggio, Maria P
|b 34
700 1 _ |a Hung, Jillian
|b 35
700 1 _ |a Herpel, Esther
|b 36
700 1 _ |a Hernandez, Brenda Y
|b 37
700 1 _ |a Hartkopf, Andreas D
|b 38
700 1 _ |a Harnett, Paul R
|b 39
700 1 _ |a Ghatage, Prafull
|b 40
700 1 _ |a García-Bueno, José M
|b 41
700 1 _ |a Gao, Bo
|b 42
700 1 _ |a Fereday, Sian
|b 43
700 1 _ |a Eilber, Ursula
|0 P:(DE-He78)cffd553d01599230a3c71996e452ca75
|b 44
|u dkfz
700 1 _ |a Edwards, Robert P
|b 45
700 1 _ |a de Sousa, Christiani B
|b 46
700 1 _ |a de Andrade, Jurandyr M
|b 47
700 1 _ |a Chudecka-Głaz, Anita
|b 48
700 1 _ |a Chenevix-Trench, Georgia
|b 49
700 1 _ |a Cazorla, Alicia
|b 50
700 1 _ |a Brucker, Sara Y
|b 51
700 1 _ |a Group, Australian Ovarian Cancer Study
|b 52
|e Collaboration Author
700 1 _ |a Alsop, Jennifer
|b 53
700 1 _ |a Whittemore, Alice S
|b 54
700 1 _ |a Steed, Helen
|b 55
700 1 _ |a Staebler, Annette
|b 56
700 1 _ |a Moysich, Kirsten B
|b 57
700 1 _ |a Menon, Usha
|b 58
700 1 _ |a Koziak, Jennifer M
|b 59
700 1 _ |a Kommoss, Stefan
|b 60
700 1 _ |a Kjaer, Susanne K
|b 61
700 1 _ |a Kelemen, Linda E
|b 62
700 1 _ |a Karlan, Beth Y
|b 63
700 1 _ |a Huntsman, David G
|b 64
700 1 _ |a Høgdall, Estrid
|b 65
700 1 _ |a Gronwald, Jacek
|b 66
700 1 _ |a Goodman, Marc T
|b 67
700 1 _ |a Gilks, Blake
|b 68
700 1 _ |a García, María José
|b 69
700 1 _ |a Fasching, Peter A
|b 70
700 1 _ |a de Fazio, Anna
|b 71
700 1 _ |a Deen, Suha
|b 72
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 73
|u dkfz
700 1 _ |a Candido Dos Reis, Francisco J
|b 74
700 1 _ |a Campbell, Ian G
|b 75
700 1 _ |a Brenton, James D
|b 76
700 1 _ |a Bowtell, David D
|b 77
700 1 _ |a Benítez, Javier
|b 78
700 1 _ |a Pharoah, Paul D P
|b 79
700 1 _ |a Köbel, Martin
|b 80
700 1 _ |a Ramus, Susan J
|b 81
700 1 _ |a Goode, Ellen L
|b 82
700 1 _ |a Bowtell, D.
|b 83
700 1 _ |a Chenevix-Trench, G.
|b 84
700 1 _ |a Green, A.
|b 85
700 1 _ |a Webb, P.
|b 86
700 1 _ |a DeFazio, A.
|b 87
700 1 _ |a Gertig, D.
|b 88
700 1 _ |a Traficante, N.
|b 89
700 1 _ |a Fereday, S.
|b 90
700 1 _ |a Moore, S.
|b 91
700 1 _ |a Hung, J.
|b 92
700 1 _ |a Harrap, K.
|b 93
700 1 _ |a Sadkowsky, T.
|b 94
700 1 _ |a Pandeya, N.
|b 95
700 1 _ |a Malt, M.
|b 96
700 1 _ |a Mellon, A.
|b 97
700 1 _ |a Robertson, R.
|b 98
700 1 _ |a Vanden Bergh, T.
|b 99
700 1 _ |a Jones, M.
|b 100
700 1 _ |a Mackenzie, P.
|b 101
700 1 _ |a Maidens, J.
|b 102
700 1 _ |a Nattress, K.
|b 103
700 1 _ |a Chiew, Y. E.
|b 104
700 1 _ |a Stenlake, A.
|b 105
700 1 _ |a Sullivan, H.
|b 106
700 1 _ |a Alexander, B.
|b 107
700 1 _ |a Ashover, P.
|b 108
700 1 _ |a Brown, S.
|b 109
700 1 _ |a Corrish, T.
|b 110
700 1 _ |a Green, L.
|b 111
700 1 _ |a Jackman, L.
|b 112
700 1 _ |a Ferguson, K.
|b 113
700 1 _ |a Martin, K.
|b 114
700 1 _ |a Martyn, A.
|b 115
700 1 _ |a Ranieri, B.
|b 116
700 1 _ |a White, J.
|b 117
700 1 _ |a Jayde, V.
|b 118
700 1 _ |a Mamers, P.
|b 119
700 1 _ |a Bowes, L.
|b 120
700 1 _ |a Galletta, L.
|b 121
700 1 _ |a Giles, D.
|b 122
700 1 _ |a Hendley, J.
|b 123
700 1 _ |a Alsop, K.
|b 124
700 1 _ |a Schmidt, T.
|b 125
700 1 _ |a Shirley, H.
|b 126
700 1 _ |a Ball, C.
|b 127
700 1 _ |a Young, C.
|b 128
700 1 _ |a Viduka, S.
|b 129
700 1 _ |a Tran, Hoa
|b 130
700 1 _ |a Bilic, Sanela
|b 131
700 1 _ |a Glavinas, Lydia
|b 132
700 1 _ |a Brooks, Julia
|b 133
700 1 _ |a Stuart-Harris, R.
|b 134
700 1 _ |a Kirsten, F.
|b 135
700 1 _ |a Rutovitz, J.
|b 136
700 1 _ |a Clingan, P.
|b 137
700 1 _ |a Glasgow, A.
|b 138
700 1 _ |a Proietto, A.
|b 139
700 1 _ |a Braye, S.
|b 140
700 1 _ |a Otton, G.
|b 141
700 1 _ |a Shannon, J.
|b 142
700 1 _ |a Bonaventura, T.
|b 143
700 1 _ |a Stewart, J.
|b 144
700 1 _ |a Begbie, S.
|b 145
700 1 _ |a Friedlander, M.
|b 146
700 1 _ |a Bell, D.
|b 147
700 1 _ |a Baron-Hay, S.
|b 148
700 1 _ |a Ferrier, A.
|b 149
700 1 _ |a Gard, G.
|b 150
700 1 _ |a Nevell, D.
|b 151
700 1 _ |a Pavlakis, N.
|b 152
700 1 _ |a Valmadre, S.
|b 153
700 1 _ |a Young, B.
|b 154
700 1 _ |a Camaris, C.
|b 155
700 1 _ |a Crouch, R.
|b 156
700 1 _ |a Edwards, L.
|b 157
700 1 _ |a Hacker, N.
|b 158
700 1 _ |a Marsden, D.
|b 159
700 1 _ |a Robertson, G.
|b 160
700 1 _ |a Beale, P.
|b 161
700 1 _ |a Beith, J.
|b 162
700 1 _ |a Carter, J.
|b 163
700 1 _ |a Dalrymple, C.
|b 164
700 1 _ |a Houghton, R.
|b 165
700 1 _ |a Russell, P.
|b 166
700 1 _ |a Links, M.
|b 167
700 1 _ |a Grygiel, J.
|b 168
700 1 _ |a Hill, J.
|b 169
700 1 _ |a Brand, A.
|b 170
700 1 _ |a Byth, K.
|b 171
700 1 _ |a Jaworski, R.
|b 172
700 1 _ |a Harnett, P.
|b 173
700 1 _ |a Sharma, R.
|b 174
700 1 _ |a Wain, G.
|b 175
700 1 _ |a Ward, B.
|b 176
700 1 _ |a Papadimos, D.
|b 177
700 1 _ |a Crandon, A.
|b 178
700 1 _ |a Cummings, M.
|b 179
700 1 _ |a Horwood, K.
|b 180
700 1 _ |a Obermair, A.
|b 181
700 1 _ |a Perrin, L.
|b 182
700 1 _ |a Wyld, D.
|b 183
700 1 _ |a Nicklin, J.
|b 184
700 1 _ |a Davy, M.
|b 185
700 1 _ |a Oehler, M. K.
|b 186
700 1 _ |a Hall, C.
|b 187
700 1 _ |a Dodd, T.
|b 188
700 1 _ |a Healy, T.
|b 189
700 1 _ |a Pittman, K.
|b 190
700 1 _ |a Henderson, D.
|b 191
700 1 _ |a Miller, J.
|b 192
700 1 _ |a Pierdes, J.
|b 193
700 1 _ |a Blomfield, P.
|b 194
700 1 _ |a Challis, D.
|b 195
700 1 _ |a McIntosh, R.
|b 196
700 1 _ |a Parker, A.
|b 197
700 1 _ |a Brown, B.
|b 198
700 1 _ |a Rome, R.
|b 199
700 1 _ |a Allen, D.
|b 200
700 1 _ |a Grant, P.
|b 201
700 1 _ |a Hyde, S.
|b 202
700 1 _ |a Laurie, R.
|b 203
700 1 _ |a Robbie, M.
|b 204
700 1 _ |a Healy, D.
|b 205
700 1 _ |a Jobling, T.
|b 206
700 1 _ |a Manolitsas, T.
|b 207
700 1 _ |a McNealage, J.
|b 208
700 1 _ |a Rogers, P.
|b 209
700 1 _ |a Susil, B.
|b 210
700 1 _ |a Sumithran, E.
|b 211
700 1 _ |a Simpson, I.
|b 212
700 1 _ |a Phillips, K.
|b 213
700 1 _ |a Rischin, D.
|b 214
700 1 _ |a Fox, S.
|b 215
700 1 _ |a Johnson, D.
|b 216
700 1 _ |a Lade, S.
|b 217
700 1 _ |a Loughrey, M.
|b 218
700 1 _ |a O'Callaghan, N.
|b 219
700 1 _ |a Murray, W.
|b 220
700 1 _ |a Waring, P.
|b 221
700 1 _ |a Billson, V.
|b 222
700 1 _ |a Pyman, J.
|b 223
700 1 _ |a Neesham, D.
|b 224
700 1 _ |a Quinn, M.
|b 225
700 1 _ |a Underhill, C.
|b 226
700 1 _ |a Bell, R.
|b 227
700 1 _ |a Ng, L. F.
|b 228
700 1 _ |a Blum, R.
|b 229
700 1 _ |a Ganju, V.
|b 230
700 1 _ |a Hammond, I.
|b 231
700 1 _ |a Leung, Y.
|b 232
700 1 _ |a McCartney, A.
|b 233
700 1 _ |a Buck, M.
|b 234
700 1 _ |a Haviv, I.
|b 235
700 1 _ |a Purdie, D.
|b 236
700 1 _ |a Whiteman, D.
|b 237
700 1 _ |a Zeps, N.
|b 238
773 _ _ |a 10.1016/j.mayocp.2017.10.023
|g Vol. 93, no. 3, p. 307 - 320
|0 PERI:(DE-600)2052617-9
|n 3
|p 307 - 320
|t Mayo Clinic proceedings
|v 93
|y 2018
|x 0025-6196
909 C O |o oai:inrepo02.dkfz.de:132628
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 30
|6 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 44
|6 P:(DE-He78)cffd553d01599230a3c71996e452ca75
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 73
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MAYO CLIN PROC : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MAYO CLIN PROC : 2015
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21